On November 20, 2024, Recursion (Nasdaq: RXRX) and Exscientia announced they had officially combined, with Exscientia becoming a wholly owned subsidiary of Recursion. The all-stock deal, first agreed in August 2024, merged two of the most prominent companies built on the premise that machine learning could industrialize the discovery of new drugs. Exscientia’s shares ceased trading and were delisted, and the combined company kept its headquarters in Salt Lake City with around 800 employees.
The two firms had complementary strengths. Recursion was known for generating enormous proprietary datasets - running automated biology experiments at scale and mapping cellular images - to find disease biology and drug candidates. Exscientia was known for AI-driven molecule design and had been among the first to put AI-designed compounds into clinical trials. Chris Gibson, Recursion’s co-founder, became chief executive of the combined company, and Exscientia’s David Hallett became chief scientific officer.
The merger arrived during a sober stretch for the sector. AI drug-discovery companies had raised large sums on bold promises, but turning computational pipelines into approved medicines remained slow, and several had seen their valuations fall sharply from earlier highs. Combining gave the merged company a broader pipeline of more than ten clinical and preclinical programs and a longer cash runway to prove the approach.
The deal is a marker of consolidation in a field moving from hype toward results. The open question it sharpened is whether scale - more data, more compute, more programs under one roof - is what finally converts AI’s speed at the front end of drug discovery into medicines that pass clinical trials.